FindTrial
Sign In

An observational retrospective study on the clinical characteristics, treatment modalities and clinical outcomes of children with advanced solid tumors treated with pembrolizumab in China

An observational retrospective study on the clinical characteristics, treatment modalities and clinical outcomes of children with advanced solid tumors treated with pembrolizumab in China

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113104
Enrollment
Unknown
Registered
2025-11-25
Start date
2025-12-22
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumors

Interventions

Observation group:None'

Sponsors

Sun Yat-sen University Cancer Prevention Center(YNMT)·
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. advanced solid tumors diagnosed from 2018 to 2024; 2. The age of first pembrolizumab monotherapy was <18 years; 3. first-line systemic therapy failed and 2L+ monotherapy with pembrolizumab.

Exclusion criteria

Exclusion criteria: 1. There was no clear first-line treatment record.

Design outcomes

Primary

MeasureTime frame
To investigate the demographic and baseline characteristics of Chinese children with advanced solid tumors;To investigate the treatment patterns of advanced solid tumors in children in China;To investigate the availability of clinical outcomes of pembrolizumab in children with advanced solid tumors in China;To qualitatively evaluate the applicability of the National Antinoplastic Drug Surveillance System (NATDSS) as a source of real-world data (RWD) for historical cohort studies;To quantitatively assess the correlation and reliability of key data elements in NATDSS;—

Countries

China

Contacts

Public ContactYizhuo Zhang

Sun Yat-sen University Cancer Prevention Center(YNMT)·

zhangyzh@sysucc.org.cn+86 20 8734 2460

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026